Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

Executive perspectives: Sir Andrew Dillon (part 2)

Continuing our market access theme pharmaphorum presents the second part of our video interview with Sir Andrew Dillon, the Chief Executive of NICE. We recently spoke with Sir Andrew Dillon, Chief Executive of the UK’s National Institute for Health and Clinical Excellence (NICE), which plays a critical role…

Articles

Device ad-vice: Giving device reps the sales tools they need

In part 3 of the "Device ad-vice" series, Meg Nohe offers advice on creating sales tools for device reps. When thinking of a medical device company’s successes, we often think of its clinical breakthroughs—developing the next “bionic” knee...

Articles

Executive perspectives: Sir Andrew Dillon (part 1)

As part of our market access month, pharmaphorum caught up with Sir Andrew Dillon, CEO of the UK’s National Institute of Health and Clinical Excellence, to hear his thoughts. Assessing the value of new medical interventions and ensuring the appropriate care pathways are in place has become ever more critical as…

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.